



Medicine: atezolizumab (brand name: Tecentriq®) for advanced urothelial carcinoma

Roche Products Limited

What is atezolizumab used for?

Atezolizumab is used to treat urothelial carcinoma, which is a cancer of the bladder and urinary tract (this includes the tubes that carry urine from the kidneys to the bladder). Advanced urothelial carcinoma may be locally advanced (spread near where it started in the bladder and urinary tract) or metastatic (spread to other parts of the body).

How does atezolizumab work?

Atezolizumab is an immunotherapy. This is a type of cancer treatment that stimulates a person's immune system (the body's natural defence system) to fight the cancer. Some cancer cells produce a protein (called PD-L1) that can switch off certain immune cells. Atezolizumab attaches to PD-L1, which prevents it from switching off these immune cells and helps the immune system fight the cancer.

What has SMC said?

SMC has not recommended atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have already received chemotherapy that contains platinum.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, SMC decided the evidence from the company was not strong enough to be certain that atezolizumab works well enough and offers value for money to NHSScotland. This was despite applying extra flexibility because atezolizumab is a medicine for a rare, end of life condition.

What does SMC's decision mean for me?

Atezolizumab should not normally be prescribed on the NHS in Scotland for use as described above. Your doctor should talk to you about other treatment options available to you. If your doctor believes that atezolizumab would be of benefit, he or she can make a request to prescribe it for you. All health boards have procedures in place to consider these requests. For further information see:

Medicines in Scotland: What's the right treatment for me?

www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisations below can provide more information and support for people with bladder cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

Action Bladder Cancer



<http://www.actionbladdercanceruk.org>



0300 302 0085

Fight Bladder Cancer



<http://www.fightbladdercancer.co.uk>



01844 351621

You can find out more about atezolizumab in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

Date advice published: 12 November 2018

SMC No: (SMC2103)